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dicult to measure, but is generally found to vary in
dierent geographic areas and in dierent racial groups.
Fuller epidemiological data allows us to focus our
education eorts in the highest-prevalence populations.
Many dierent variants of the protein exist, but the most
frequent deficient allele is the Z allele, with most of the
detected patients being homozygous for this mutation. To
investigate the prevalence of this deficiency in dierent
countries, we reviewed the results of population screening
and other studies.
Two important studies performed in Sweden and the
United States, respectively, used large data pools to
estimate the incidence in the general population of those
countries. The Swedish investigation, conducted between
1972 and 1974, screened 200 000 newborns. The results
showed one homozygous ZZ per 1600 newborns (0?06%)
(1). In the U.S. study conducted in 1988, 20 000 blood
donors were screened. There, one homozygous ZZ was
observed per 2850 healthy blood donors (0?03%) (2).
A classic investigation by Fagerhol studied sailors that
went to the coast of Norway. The results from this early
study suggested that a gradient in the prevalence of this
variant existed between northern Europe and the southern
countries of Europe (3). From more recent investigations,
we observe a higher prevalence of the variant in the south of
Sweden (4), in Denmark (5), and in Holland (6), which
reaches a 2% gene frequency for the Z allele. The
prevalence is lower in the northern areas of Scandinavia
(Fig. 1). A high prevalence is also observed in Great Britain
(7), with numbers that are close to those observed in
Denmark, or in south Sweden (Fig. 2). The prevalence is
not as high in Germany (8), however, where it reaches
about 1?3% in some areas of the country only (Fig. 3).
Similarly for France (9), where the prevalence is from 1?8%
in the north to 1?3% in the center and 1?4% near Lyon (10)
(Fig. 4). In Italy, there seems to be a gradient from north to
south (11,12) (Fig. 5).
Regarding Spain, a study was performed in Catalonia
(northeast Spain) in which it was observed that 3% of the
adult population was heterozygous MZ (13). Thus, the gene
frequency of the Z allele was 1?5% in Spain. [Note that the
number is not zero in the Basque country. Though others
have thought that the Z allele does not exist among theCorrespondence should be addressed to: Marc Miravitlles, MD,
Department of Pneumology, Vall d’Hebron Hospital, Pg. Vall
d’Hebron 119-129, 08035 Barcelona, Spain.
0954-6111/00/0C00S12+04 $35?00/0Basques, we have observed in some studies and from
National Registry data that people of Basque descent also
have the Z allele (14).] In Spain overall, as in France and
Italy, there seems to be a gradient of higher prevalence in
the north with lower prevalence going south and east (Fig.
6). Looking at all the European countries together, there is
a pattern of zones of prevalence to be observed (Fig. 7).
In the United States, similar numbers have been observed
for the Z allele, but there are notable dierences between
races. For instance, the Z variant is almost unknown
among blacks. It is also very rare in Japan, where in most
cases the deficiency is caused by other variants, like S
siiyama (15). Other studies have shown the Z allele to be
almost non-existent among Japanese (16) and blacks (17).
As another example of racial variation, a 1992 study in the
Jewish population on the island of Majorca showed very
low prevalence, about 0?35% (18).
Since we know the prevalence of this disease and
we know how it is inherited, we can calculate the number
of deficient individuals expected in a given population.
For instance, in Spain, based on the Hardy–Weinberg
equilibrium population model, one can expect the number
of deficient individuals to be about 4000 homozygous
PiZZ.
The S allele is another interesting variant. It also shows a
gradient in Europe, but a dierent one, being highest in the
west and decreasing towards the east (Fig. 8).
Based on these figures for the prevalence of a1-anti-
trypsin deficiency, one realizes that to be able to predict the
frequency of the disease, having registries is vital for
gathering information and conducting studies. This is
important for the diagnosis and well-being of future
patients. AAT deficiency is largely undiagnosed, and as a
result the World Health Organization recommends screen-
ing for a1-antitrypsin deficiency at least once in all patients
with chronic obstructive pulmonary disease, and in
adolescents and adults with asthma (19).
There are well-known and well-established a1-anti-
trypsin registries in northern Europe, such as the Danish,
the Swedish, and the German registries. But even in
countries with lower prevalence and a shorter tradition of
the study of serpins and a1-antitrypsin, there has been an
increasing awareness of the disease.
In Italy, for example, individuals with missing or reduced
a1 band, with plasma and a1 levels below 80mgdl
71, or
early onset emphysema, and also first-degree relatives of
deficient or heterozygous individuals are screened. The
screening is carried out via dried blood spots on filter paper# 2000 HARCOURT PUBLISHERS LTD
FIGS 1–6. Gene frequency of the Z allele in European countries (% prevalence).
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proved a very successful experience. In 5 years, there were
almost 2000 individuals screened, and a total of 151deficient subjects were identified. More than 118 of the
151 were PiZZ, with an identification rate of 12?1% and
monthly identification rate of 2?3 (20).
FIG. 7. Gene frequency of the Z allele in Europe (% prevalence).
FIG. 8. Gene frequency of the S allele in Europe (% prevalence).
S14 M. MIRAVITLLESIn Spain, a registry was founded in 1993, as a workshop
of the Spanish Society of Pneumology and Thoracic
Surgery. It started with just 45 patients coming from seven
of the 17 regions in Spain. (As shown earlier, there is an
expected population of 4000 PiZZ in Spain.) The organiza-
tion consists of a co-ordinating centre in Barcelona, a
steering committee with seven members and 64 participat-ing centres: 63 in Spain and one in Andorra. We organize
an annual conference of delegates, who review the database
and plan for possible future studies. Criteria for therapy
that can be applied in our country and also local guidelines
for management are discussed. The registry is active in a
number of important activities, such as managing the
shortage of Prolastin1 that we suered in the last 2 years,
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trypsin deficiency and generating publications. Most of the
publications were in local journals and promoted awareness
of the disease among our colleagues. This registry has
definitely been a success in at least one way because the
number of patients enrolled in the registry has increased to
more than 250 (14,21).
The existence of the registry has allowed us to develop a
central laboratory which can pursue the phenotyping, and
even genotyping, studies and has allowed us to discover some
new variants of the deficiency. For instance, in a patient with
severe emphysema, we discovered a variant which we called
Ybarcelona that includes mutation in exon 3 and also in exon 5
(22). We discovered another variant that is located in exon 5,
in position 369, in which there was a new substitution, in that
it was in the same codon as the variant already known in
Mheerlen but in a dierent pair of bases. The variant had a
very low activity, so it seems that this position is very
important for the activity of the molecule (23).
In general, it is important to be aware that a1-antitrypsin
deficiency is an under-diagnosed condition. Approximately
3% of individuals of European descent are heterozygous
MZ, which means that between 70 000 and 120 000 a1-anti-
trypsin deficient individuals exist in western European
countries alone. The activity of registries is very important
in screening for, and documenting, this condition.
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